[go: up one dir, main page]

MEP56408A - Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes - Google Patents

Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes

Info

Publication number
MEP56408A
MEP56408A MEP-564/08A MEP56408A MEP56408A ME P56408 A MEP56408 A ME P56408A ME P56408 A MEP56408 A ME P56408A ME P56408 A MEP56408 A ME P56408A
Authority
ME
Montenegro
Prior art keywords
conjugates
production
biological membranes
methods
molecules via
Prior art date
Application number
MEP-564/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Eugen Uhlmann
Beate Greiner
Eberhard Unger
Gislinde Gothe
Marc Schwerdel
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MEP56408A publication Critical patent/MEP56408A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
MEP-564/08A 1999-07-28 2000-07-20 Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes MEP56408A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19935302A DE19935302A1 (de) 1999-07-28 1999-07-28 Konjugate und Verfahren zu deren Herstellung sowie deren Verwendung zum Transport von Molekülen über biologische Membranen
YUP-903/01A RS51447B (sr) 1999-07-28 2000-07-20 Konjugati i postupci za njihovu proizvodnju, i njihova upotreba za transport molekula kroz biološke membrane
PCT/EP2000/006936 WO2001008707A2 (de) 1999-07-28 2000-07-20 Konjugate und verfahren zu deren herstellung sowie deren verwendung zum transport von molekülen über biologische membranen

Publications (1)

Publication Number Publication Date
MEP56408A true MEP56408A (en) 2011-05-10

Family

ID=7916258

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-564/08A MEP56408A (en) 1999-07-28 2000-07-20 Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes

Country Status (32)

Country Link
US (1) US8420396B2 (sh)
EP (1) EP1204430B1 (sh)
JP (1) JP4791665B2 (sh)
KR (1) KR100721696B1 (sh)
CN (1) CN1227035C (sh)
AR (1) AR029385A1 (sh)
AT (1) ATE447413T1 (sh)
AU (1) AU776114B2 (sh)
BR (1) BR0012757A (sh)
CA (1) CA2377977C (sh)
CY (1) CY1109744T1 (sh)
CZ (1) CZ2002300A3 (sh)
DE (2) DE19935302A1 (sh)
DK (1) DK1204430T3 (sh)
EE (1) EE05303B1 (sh)
ES (1) ES2335741T3 (sh)
HR (1) HRP20020074B1 (sh)
HU (1) HUP0201995A3 (sh)
IL (2) IL147527A0 (sh)
ME (1) MEP56408A (sh)
MX (1) MXPA01013114A (sh)
NO (1) NO334155B1 (sh)
NZ (1) NZ516838A (sh)
PL (1) PL202881B1 (sh)
PT (1) PT1204430E (sh)
RS (2) RS20100249A (sh)
RU (1) RU2275936C2 (sh)
SI (1) SI1204430T1 (sh)
SK (1) SK287654B6 (sh)
TR (4) TR200706709T2 (sh)
WO (1) WO2001008707A2 (sh)
ZA (1) ZA200200657B (sh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US7026166B2 (en) * 2002-01-22 2006-04-11 Chiron Corporation Fluorogenic dyes
US7704756B2 (en) 2003-01-21 2010-04-27 Novartis Vaccines And Diagnostics, Inc. Fluorogenic dyes
ATE520784T1 (de) * 2003-09-11 2011-09-15 Universitaetsklinikum Schleswig Holstein Campus Luebeck Den transmembrantransport von nukleinsäuren fördernde nukleotidsequenzen
CA2536139A1 (en) * 2003-09-25 2005-04-07 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
EP1886681A3 (en) * 2004-10-07 2008-11-19 Sulfidris S.r.l. 5-(p-hydroxyphenyl)-3H-1,2-dithiol-3-thione valproate ester
KR100690199B1 (ko) * 2006-04-20 2007-03-12 이화여자대학교 산학협력단 구리 이온 선택성을 갖는 플루오레세인 유도체, 이의제조방법 및 이를 이용한 생체 내 구리 이온 검출방법
KR20100068422A (ko) * 2007-10-09 2010-06-23 콜리 파마슈티칼 게엠베하 변경된 당 잔기를 함유하는 면역자극성 올리고뉴클레오티드 유사체
KR20130108655A (ko) 2010-12-29 2013-10-04 에프. 호프만-라 로슈 아게 핵산의 세포내 전달을 위한 소분자 접합체
MX381946B (es) 2014-05-23 2025-03-13 Genzyme Corp Restos oligonucleotidicos multiples sobre soporte peptidico.
EP3493855A4 (en) * 2016-08-02 2020-04-01 ISI Life Sciences, Inc. COMPOSITIONS AND METHOD FOR DETECTING CANCER CELLS IN A TISSUE SAMPLE
US20180036312A1 (en) * 2016-08-02 2018-02-08 ISI Life Sciences Inc. Novel Scaffolds for Intracellular Compound Delivery for the Detection of Cancer Cells
US10539567B2 (en) * 2017-05-15 2020-01-21 Indicator Systems International, Inc. Biopsy methods and devices
US10753942B2 (en) 2017-05-15 2020-08-25 Indicator Systems International, Inc. Methods to detect remnant cancer cells
KR20230096856A (ko) 2021-12-22 2023-06-30 한국과학기술연구원 신규 펩타이드-올리고뉴클레오티드 접합체 및 이의 용도

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8801070D0 (sv) * 1988-03-23 1988-03-23 Pharmacia Ab Method for immobilizing a dna sequence on a solid support
US5354844A (en) * 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
WO1995006659A1 (en) * 1992-07-01 1995-03-09 Isis Pharmaceuticals, Inc. Amine-derivatized nucleosides and oligonucleosides
US6228982B1 (en) * 1992-05-22 2001-05-08 Benget Norden Double-stranded peptide nucleic acids
US6335434B1 (en) * 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
NZ245720A (en) 1992-01-22 1995-12-21 Hoechst Ag Oligonucleotide analogues; use as gene expression inhibitor or dna probe
US6033909A (en) * 1992-01-22 2000-03-07 Hoechst Aktiengesellschaft Oligonucleotide analogs, their preparation and use
US5633360A (en) * 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
RU2094059C1 (ru) * 1993-08-30 1997-10-27 Московский государственный университет, химический факультет Способ транспорта нейротропных препаратов в мозг
US5820873A (en) * 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
RU2127606C1 (ru) * 1994-12-23 1999-03-20 Санкт-Петербургский государственный университет Способ получения растворимых ковалентных конъюгатов
DE19502912A1 (de) * 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilisierte Oligonucleotide
US5698411A (en) * 1995-05-18 1997-12-16 Coulter Corporation Method for determining activity of enzymes in metabolically active whole cells
WO1998020887A1 (en) * 1996-11-14 1998-05-22 Brigham And Women's Hospital, Inc. Polyphosphoinositide binding peptides for intracellular drug delivery
GB9809084D0 (en) 1998-04-28 1998-06-24 Nycomed Imaging As Improvements in or relating to diagnostic/therapeutic agents
DE19824535A1 (de) * 1998-06-03 1999-12-09 Roche Diagnostics Gmbh Neue Rhodamin-Derivate und deren Verwendung
US6335432B1 (en) 1998-08-07 2002-01-01 Bio-Red Laboratories, Inc. Structural analogs of amine bases and nucleosides
US6080580A (en) * 1998-10-05 2000-06-27 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of tumor necrosis factor-α (TNF-α) expression
US7005123B1 (en) 1999-06-17 2006-02-28 Universiteit Gent Functional poly-α-amino-acid derivatives useful for the modification of biologically active materials and their application

Also Published As

Publication number Publication date
NO20020367L (no) 2002-03-26
RS51447B (sr) 2011-04-30
NO20020367D0 (no) 2002-01-23
PL353069A1 (en) 2003-10-06
WO2001008707A3 (de) 2001-11-08
KR100721696B1 (ko) 2007-05-28
AR029385A1 (es) 2003-06-25
IL147527A (en) 2006-08-01
DK1204430T3 (da) 2010-03-29
ES2335741T3 (es) 2010-04-05
SK1172002A3 (en) 2002-08-06
DE50015781D1 (de) 2009-12-17
RS20100249A (sr) 2011-02-28
DE19935302A1 (de) 2001-02-08
CN1360507A (zh) 2002-07-24
YU90301A (sh) 2004-05-12
AU6825200A (en) 2001-02-19
SI1204430T1 (sl) 2010-03-31
US8420396B2 (en) 2013-04-16
TR200200222T2 (tr) 2002-07-22
PL202881B1 (pl) 2009-07-31
CA2377977A1 (en) 2001-02-08
HRP20020074B1 (en) 2011-01-31
CN1227035C (zh) 2005-11-16
EP1204430A2 (de) 2002-05-15
ZA200200657B (en) 2003-09-23
EP1204430B1 (de) 2009-11-04
HRP20020074A2 (en) 2005-10-31
JP2003505517A (ja) 2003-02-12
HUP0201995A2 (en) 2002-10-28
ATE447413T1 (de) 2009-11-15
CZ2002300A3 (cs) 2002-05-15
HUP0201995A3 (en) 2005-02-28
EE200200035A (et) 2003-04-15
KR20020031392A (ko) 2002-05-01
SK287654B6 (sk) 2011-05-06
US20080071069A1 (en) 2008-03-20
CA2377977C (en) 2011-09-20
IL147527A0 (en) 2002-08-14
TR201109493T2 (tr) 2012-03-21
RU2275936C2 (ru) 2006-05-10
NO334155B1 (no) 2013-12-23
HK1047042A1 (en) 2003-02-07
EE05303B1 (et) 2010-06-15
MXPA01013114A (es) 2002-06-04
BR0012757A (pt) 2002-04-02
CY1109744T1 (el) 2014-09-10
AU776114B2 (en) 2004-08-26
NZ516838A (en) 2004-07-30
PT1204430E (pt) 2010-01-26
JP4791665B2 (ja) 2011-10-12
TR200706709T2 (tr) 2008-02-21
WO2001008707A2 (de) 2001-02-08
TR201109491T2 (tr) 2012-02-21

Similar Documents

Publication Publication Date Title
MEP56408A (en) Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes
WO2003104418A3 (en) Reconstituted polypeptides
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
BRPI0407397A (pt) Evento de algodão mon 88913 e composições e métodos para sua detecção
ECSP066461A (es) Método para activar las poblaciones de célula especificas utilizando conjugados maitansinoides del agente de enlace celular enlazados a través de un enlazador no divisible, dichos conjugados, y métodos para hacer dichos conjugados
WO2006076691A8 (en) Irta-2 antibodies and their uses
BRPI0514537B8 (pt) compostos de aminoeteroarila substituídos com pirazol e composição farmacêutica que os compreende
WO2007002223A3 (en) Cd19 antibodies and their uses
BR0210599A (pt) Uso de monóxido de carbono, método para manutenção de uma célula animal in vitro, artigo de manufatura, bem como meio celular estéril
BR0114199A (pt) Sequências de nucleotìdeos que medeiam a fertilidade masculina e métodos de uso das mesmas
WO2005097185A3 (en) Irta-5 antibodies and their uses
NO20030856L (no) Membranpenetrerende peptider og anvendelse av disse
NO20051030L (no) Funksjonelle kardiomyocytter fra humane embryonale stamceller
IL172854A0 (en) Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations
DK1654253T3 (da) Substituerede 3-pyrrolidinindolderivater
ATE480261T1 (de) Konjugat zur vermittlung eines zell-, kompartiment- oder membranspezifischen transports von wirksubstanzen
BRPI0410562A (pt) molécula recombinante e veìculo para expressão, liberação e purificação de polipeptìdeos alvo
UY28558A1 (es) Proteína
WO2001042283A3 (en) Sex-chromosome-specific proteins, species specific and sperm specific proteins and methods for their identification and isolation
IL161341A (en) Sensitivity controls for blood serology prepared from modified cells
DK1051491T3 (da) Equin Fc Epsilon receptor-alfa-kæde-nukleinsyremolekyler, korresponderende proteiner og anvendelse heraf
AR045671A1 (es) Moleculas de union de nogo a y su uso farmaceutico
WO2003086273A8 (en) Histone conjugates and uses thereof
ATE415470T1 (de) Herstellungsverfahren für iturin a und dessen homologe
DE50213507D1 (de) Verfahren und mittel zur beeinflussung von interzellulärer kommunikation und interzellulärem organellentransport